FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760156961> ?p ?o ?g. }

• W2760156961 endingPage "E525" @default.
• W2760156961 startingPage "E524" @default.
• W2760156961 abstract "To evaluate effectiveness of fentanyl pectin nasal citrate (FPNC) in controlling breakthrough pain episodes (BPE) in cancer patients (pts) undergoing radiotherapy provoked by routine radiotherapy procedures that impede its realization. Fifty eight consecutive pts, who presented BPE associated to routine radiotherapy procedures (simulation, imaging acquisition and treatment administration) that impeded its accomplishment, were included in the study. BPE intensity was evaluated by Visual Analog Scale (VAS) after the procedure that triggered them, and after the administration of FPNC. All pts described a very high VAS value (mean: 8.8; range: 7-10) related with the specific procedure. The administration of FPNC was performed according our department protocol. 87.9% of the pts were already receiving an opioid basal treatment equivalent to 40-160 mg morphine. For every FPNC administration, data related to response, degree of pain relief, onset of the relief, need of new FPNC administration and fulfilment of the procedure were collected. Age: Mean 62.5 years (range: 42-89). Gender: 36 males and 22 females. Primary tumor: lung 24 pts, prostate 12, breast 11, gynecological 4, digestive 2 and others 5. 53 pts (91.3%) suffered from bone metastases. Procedure that triggered the BPE: Simulation 46 pts and treatment administration 12. In 49 pts (84.5%) VAS score was reduced to 4.8 (range 2-6) after 4.5 minutes (range: 2-10) of first FPNC administration. 9 pts (15.5%) dis not responded after 15 minutes and required a second dose of FPNC. All of them responded and the VAS score was reduced to 4.6 (range 4-6) after 3 minutes of second administration. No side effects related to the FPNC administration were reported. In 84.5% of the patients the procedure was performed after 4.5 minutes. Some procedures in the radiotherapy process may trigger BPE episodes which impede its accomplishment. In our study, FPNC has proven to be very effective in the BPE management, allowing the accomplishment of these procedures in a short time, avoiding delays and unnecessary suffering to patients." @default.
• W2760156961 created "2017-10-06" @default.
• W2760156961 creator A5007747436 @default.
• W2760156961 creator A5022345648 @default.
• W2760156961 creator A5025516318 @default.
• W2760156961 creator A5035587694 @default.
• W2760156961 creator A5040575395 @default.
• W2760156961 creator A5074561275 @default.
• W2760156961 creator A5080005808 @default.
• W2760156961 date "2017-10-01" @default.
• W2760156961 modified "2023-10-18" @default.
• W2760156961 title "Effectiveness of Fentanyl Pectin Nasal Citrate in Controlling Breakthrough Pain Episodes Caused by Routine Radiation Therapy Procedures" @default.
• W2760156961 doi "https://doi.org/10.1016/j.ijrobp.2017.06.1859" @default.
• W2760156961 hasPublicationYear "2017" @default.
• W2760156961 type Work @default.
• W2760156961 sameAs 2760156961 @default.
• W2760156961 citedByCount "1" @default.
• W2760156961 countsByYear W27601569612019 @default.
• W2760156961 crossrefType "journal-article" @default.
• W2760156961 hasAuthorship W2760156961A5007747436 @default.
• W2760156961 hasAuthorship W2760156961A5022345648 @default.
• W2760156961 hasAuthorship W2760156961A5025516318 @default.
• W2760156961 hasAuthorship W2760156961A5035587694 @default.
• W2760156961 hasAuthorship W2760156961A5040575395 @default.
• W2760156961 hasAuthorship W2760156961A5074561275 @default.
• W2760156961 hasAuthorship W2760156961A5080005808 @default.
• W2760156961 hasBestOaLocation W27601569611 @default.
• W2760156961 hasConcept C126322002 @default.
• W2760156961 hasConcept C141071460 @default.
• W2760156961 hasConcept C14184104 @default.
• W2760156961 hasConcept C170493617 @default.
• W2760156961 hasConcept C2777389121 @default.
• W2760156961 hasConcept C2778311950 @default.
• W2760156961 hasConcept C2781063702 @default.
• W2760156961 hasConcept C2781072394 @default.
• W2760156961 hasConcept C42219234 @default.
• W2760156961 hasConcept C71924100 @default.
• W2760156961 hasConceptScore W2760156961C126322002 @default.
• W2760156961 hasConceptScore W2760156961C141071460 @default.
• W2760156961 hasConceptScore W2760156961C14184104 @default.
• W2760156961 hasConceptScore W2760156961C170493617 @default.
• W2760156961 hasConceptScore W2760156961C2777389121 @default.
• W2760156961 hasConceptScore W2760156961C2778311950 @default.
• W2760156961 hasConceptScore W2760156961C2781063702 @default.
• W2760156961 hasConceptScore W2760156961C2781072394 @default.
• W2760156961 hasConceptScore W2760156961C42219234 @default.
• W2760156961 hasConceptScore W2760156961C71924100 @default.
• W2760156961 hasIssue "2" @default.
• W2760156961 hasLocation W27601569611 @default.
• W2760156961 hasOpenAccess W2760156961 @default.
• W2760156961 hasPrimaryLocation W27601569611 @default.
• W2760156961 hasRelatedWork W2024003832 @default.
• W2760156961 hasRelatedWork W2061463537 @default.
• W2760156961 hasRelatedWork W2074008392 @default.
• W2760156961 hasRelatedWork W2076138499 @default.
• W2760156961 hasRelatedWork W2079890364 @default.
• W2760156961 hasRelatedWork W2122417826 @default.
• W2760156961 hasRelatedWork W2329858839 @default.
• W2760156961 hasRelatedWork W2333740563 @default.
• W2760156961 hasRelatedWork W2549135832 @default.
• W2760156961 hasRelatedWork W4241337072 @default.
• W2760156961 hasVolume "99" @default.
• W2760156961 isParatext "false" @default.
• W2760156961 isRetracted "false" @default.
• W2760156961 magId "2760156961" @default.
• W2760156961 workType "article" @default.